Literature DB >> 34043283

Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020-2060).

Kumar B Rajan1, Jennifer Weuve2, Lisa L Barnes3, Elizabeth A McAninch1, Robert S Wilson3, Denis A Evans1.   

Abstract

INTRODUCTION: The estimate of people with clinical Alzheimer's disease (AD) and mild cognitive impairment provides an understanding of the disease burden.
METHODS: We estimated people with cognitive impairment using a quasibinomial regression model in 10,342 participants with cognitive test scores.
RESULTS: The 2020 US Census-adjusted prevalence of clinical AD was 11.3% (95% confidence interval [CI] = 10.7-11.9): 10.0% among non-Hispanic Whites, 14.0% among Hispanics, and 18.6% among non-Hispanic Blacks. We estimate that in 2020, 6.07 (95% CI = 5.75-6.38) million people were living with clinical AD, which increases to 13.85 (95% CI = 12.98-14.74) million in 2060, 423% higher among Hispanics, 192% higher among Blacks, and 63% higher among Whites. However, there are predicted to be more significant increases in later years among those over 85 and women compared to men. DISCUSSION: The number of people with clinical AD will increase as the "baby boom" generation reaches older ages, exerting a strong upward influence on disease burden.
© 2021 the Alzheimer's Association.

Entities:  

Keywords:  2020 US prevalence; clinical Alzheimer's disease; forecasting; mild cognitive impairment

Mesh:

Year:  2021        PMID: 34043283      PMCID: PMC9013315          DOI: 10.1002/alz.12362

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   16.655


  31 in total

1.  Cognitive activity and incident AD in a population-based sample of older persons.

Authors:  R S Wilson; D A Bennett; J L Bienias; N T Aggarwal; C F Mendes De Leon; M C Morris; J A Schneider; D A Evans
Journal:  Neurology       Date:  2002-12-24       Impact factor: 9.910

2.  Direct medical costs and source of cost differences across the spectrum of cognitive decline: a population-based study.

Authors:  Cynthia L Leibson; Kirsten Hall Long; Jeanine E Ransom; Rosebud O Roberts; Steven L Hass; Amy M Duhig; Carin Y Smith; Jane A Emerson; V Shane Pankratz; Ronald C Petersen
Journal:  Alzheimers Dement       Date:  2015-04-06       Impact factor: 21.566

3.  The US economic and social costs of Alzheimer's disease revisited.

Authors:  R L Ernst; J W Hay
Journal:  Am J Public Health       Date:  1994-08       Impact factor: 9.308

4.  Population distribution and redistribution of the baby-boom cohort in the United States: recent trends and implications.

Authors:  Peter A Rogerson; Daejong Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-17       Impact factor: 11.205

5.  Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer's disease.

Authors:  M Albert; L A Smith; P A Scherr; J O Taylor; D A Evans; H H Funkenstein
Journal:  Int J Neurosci       Date:  1991-04       Impact factor: 2.292

6.  Age-specific incidence of Alzheimer's disease in a community population.

Authors:  L E Hebert; P A Scherr; L A Beckett; M S Albert; D M Pilgrim; M J Chown; H H Funkenstein; D A Evans
Journal:  JAMA       Date:  1995-05-03       Impact factor: 56.272

Review 7.  Dementia prevention, intervention, and care.

Authors:  Gill Livingston; Andrew Sommerlad; Vasiliki Orgeta; Sergi G Costafreda; Jonathan Huntley; David Ames; Clive Ballard; Sube Banerjee; Alistair Burns; Jiska Cohen-Mansfield; Claudia Cooper; Nick Fox; Laura N Gitlin; Robert Howard; Helen C Kales; Eric B Larson; Karen Ritchie; Kenneth Rockwood; Elizabeth L Sampson; Quincy Samus; Lon S Schneider; Geir Selbæk; Linda Teri; Naaheed Mukadam
Journal:  Lancet       Date:  2017-07-20       Impact factor: 202.731

Review 8.  Recent global trends in the prevalence and incidence of dementia, and survival with dementia.

Authors:  Martin Prince; Gemma-Claire Ali; Maëlenn Guerchet; A Matthew Prina; Emiliano Albanese; Yu-Tzu Wu
Journal:  Alzheimers Res Ther       Date:  2016-07-30       Impact factor: 6.982

9.  A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II.

Authors:  Fiona E Matthews; Antony Arthur; Linda E Barnes; John Bond; Carol Jagger; Louise Robinson; Carol Brayne
Journal:  Lancet       Date:  2013-07-17       Impact factor: 79.321

10.  The worldwide costs of dementia 2015 and comparisons with 2010.

Authors:  Anders Wimo; Maëlenn Guerchet; Gemma-Claire Ali; Yu-Tzu Wu; A Matthew Prina; Bengt Winblad; Linus Jönsson; Zhaorui Liu; Martin Prince
Journal:  Alzheimers Dement       Date:  2016-08-29       Impact factor: 21.566

View more
  45 in total

1.  Racial/ethnic disparities in the enrollment of Medication Therapy Management programs among Medicare beneficiaries with Alzheimer's disease and related dementias.

Authors:  Jamie A Browning; Chi Chun Steve Tsang; Rose Zeng; Xiaobei Dong; Joseph Garuccio; Jim Y Wan; Marie A Chisholm-Burns; Christopher K Finch; Jack W Tsao; Junling Wang
Journal:  Curr Med Res Opin       Date:  2022-08-09       Impact factor: 2.705

Review 2.  Aduhelm, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer's Disease: A comprehensive review.

Authors:  Hannah W Haddad; Garett W Malone; Nicholas J Comardelle; Arielle E Degueure; Salomon Poliwoda; Rachel J Kaye; Kevin S Murnane; Adam M Kaye; Alan D Kaye
Journal:  Health Psychol Res       Date:  2022-07-28

3.  Aducanumab, a Novel Anti-Amyloid Monoclonal Antibody, for the Treatment of Alzheimer's Disease: A Comprehensive Review.

Authors:  Hannah W Haddad; Garett W Malone; Nicholas J Comardelle; Arielle E Degueure; Adam M Kaye; Alan D Kaye
Journal:  Health Psychol Res       Date:  2022-01-30

4.  Amyloid-Related Imaging Abnormalities with Emerging Alzheimer Disease Therapeutics: Detection and Reporting Recommendations for Clinical Practice.

Authors:  P M Cogswell; J A Barakos; F Barkhof; T S Benzinger; C R Jack; T Y Poussaint; C A Raji; V K Ramanan; C T Whitlow
Journal:  AJNR Am J Neuroradiol       Date:  2022-08-11       Impact factor: 4.966

Review 5.  Heart health meets cognitive health: evidence on the role of blood pressure.

Authors:  Priya Palta; Marilyn S Albert; Rebecca F Gottesman
Journal:  Lancet Neurol       Date:  2021-10       Impact factor: 59.935

Review 6.  APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer's disease pathology and brain diseases.

Authors:  Rosalía Fernández-Calle; Sabine C Konings; Javier Frontiñán-Rubio; Juan García-Revilla; Lluís Camprubí-Ferrer; Martina Svensson; Isak Martinson; Antonio Boza-Serrano; José Luís Venero; Henrietta M Nielsen; Gunnar K Gouras; Tomas Deierborg
Journal:  Mol Neurodegener       Date:  2022-09-24       Impact factor: 18.879

7.  Anesthesia promotes acute expression of genes related to Alzheimer's disease and latent tau aggregation in transgenic mouse models of tauopathy.

Authors:  John David Eun; Heidy Jimenez; Leslie Adrien; Adam Wolin; Philippe Marambaud; Peter Davies; Jeremy L Koppel
Journal:  Mol Med       Date:  2022-07-20       Impact factor: 6.376

Review 8.  Biomarkers for Alzheimer's Disease in the Current State: A Narrative Review.

Authors:  Serafettin Gunes; Yumi Aizawa; Takuma Sugashi; Masahiro Sugimoto; Pedro Pereira Rodrigues
Journal:  Int J Mol Sci       Date:  2022-04-29       Impact factor: 6.208

Review 9.  Friend or Foe? Defining the Role of Glutamate in Aging and Alzheimer's Disease.

Authors:  MaKayla F Cox; Erin R Hascup; Andrzej Bartke; Kevin N Hascup
Journal:  Front Aging       Date:  2022-06-16

10.  Regional variation in U.S dementia trends from 2000-2012.

Authors:  Jennifer A Ailshire; Katrina M Walsemann; Calley E Fisk
Journal:  SSM Popul Health       Date:  2022-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.